Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer. Through these filings, investors can review Rigel’s official disclosures on its commercial portfolio, clinical pipeline and financial condition.
Rigel’s SEC submissions include current reports on Form 8-K that furnish press releases such as quarterly financial results and business updates. For example, recent 8-K filings reference press releases titled “Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update” and “Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update.” These documents outline total revenues, net product sales from TAVALISSE, GAVRETO and REZLIDHIA, contract revenues from collaborations, costs and expenses, net income, and cash, cash equivalents and short-term investments.
Filings also confirm key corporate details, including that Rigel Pharmaceuticals, Inc. is incorporated in Delaware and that its common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol RIGL. Investors can use these records to verify listing status, security information and the company’s description as a biotechnology business dedicated to therapies for hematologic disorders and cancer.
On Stock Titan’s SEC filings page, users can follow Rigel’s real-time submissions from the SEC’s EDGAR system, including Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements. AI-powered summaries help explain the key points of lengthy filings, highlighting items such as revenue composition, collaboration-related contract revenues, and updates on clinical programs like the Phase 1b study of R289 in lower-risk myelodysplastic syndrome.
In addition, the platform can surface insider transaction reports on Form 4 when filed, giving users a view into equity awards and other insider activity. By combining original SEC documents with AI-generated insights, this page is intended to make Rigel’s regulatory disclosures more accessible to both individual and professional investors.
Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition. As EVP & Chief Financial Officer, he had 3,546 shares of Rigel Pharmaceuticals common stock withheld on February 10, 2026 to cover tax obligations at a price of $34.62 per share.
After this tax-withholding disposition, he directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The filing characterizes the transaction as payment of a tax liability by delivering securities, rather than an open-market sale.
Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.
Rigel Pharmaceuticals executive David A. Santos reported a routine share disposition related to tax withholding. On 02/10/2026, 3,546 shares of common stock were disposed of at $34.62 per share to satisfy tax obligations associated with equity compensation. After this transaction, he directly owned 43,440 shares of Rigel common stock.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes. On 02/10/2026, 7,607 shares of common stock were withheld at $34.62 per share in a transaction coded “F,” which indicates payment of tax liability by delivering securities.
After this tax-withholding disposition, Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This filing reflects an administrative equity and tax event rather than an open-market purchase or sale.
Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction. As EVP and Chief Medical Officer, she disposed of 3,758 shares of common stock on February 10, 2026 through a tax-withholding arrangement at $34.62 per share.
After this transaction, she directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. The transaction was coded as a payment of tax liability by delivering securities, which is typically associated with equity compensation events rather than an open-market sale.
State Street Corporation, a Massachusetts-based financial institution, has disclosed a passive ownership stake in Rigel Pharmaceuticals, Inc. common stock. As of the event date of 12/31/2025, State Street beneficially owned 1,091,223 shares, representing 6% of Rigel’s outstanding common stock.
State Street reports no sole voting or dispositive power over the shares. It has shared voting power over 1,064,192 shares and shared dispositive power over 1,091,223 shares, held through affiliated investment adviser subsidiaries including SSGA Funds Management, Inc. The holdings are certified as being in the ordinary course of business and not for influencing control of Rigel.
Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock. On 02/02/2026, he disposed of 5,718 shares of Rigel common stock at $36.01 per share in a transaction coded "F." After this transaction, he beneficially owned 46,986 shares, held directly. A footnote explains that this balance includes 1,000 shares acquired under the issuer's stock purchase plan.
Rigel Pharmaceuticals executive Dean L. Schorno, EVP & Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 02/02/2026, 5,488 shares of common stock were disposed of in a transaction coded "F" at a price of $36.01 per share.
Following this transaction, Schorno beneficially owned 59,247 shares of Rigel common stock in direct ownership. This total includes 500 shares acquired under Rigel’s stock purchase plan, as noted in the filing’s footnote.
Rigel Pharmaceuticals executive Raymond J. Furey, EVP, GC, CCO & Corp Sec, reported a disposition of common stock. On February 2, 2026, he disposed of 3,968 shares of Rigel common stock at $36.01 per share, reported with transaction code F.
After this transaction, Furey directly beneficially owned 35,862 common shares, which the disclosure notes includes 1,000 shares acquired under Rigel’s stock purchase plan.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported multiple insider stock transactions. On January 26, 2026, he exercised employee stock options in two 40,000-share lots at $27.40 per share and reported related dispositions of 35,211 and 35,424 common shares at $37 per share.
On February 2, 2026, he reported an additional disposition of 14,110 common shares at $36.01 per share. After these transactions, he directly beneficially owned 235,709 Rigel common shares, including 1,000 shares acquired under the company’s stock purchase plan. All share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.